{"prompt": "['Product: MK-3475', '91', 'Protocol/Amendment No.: 604-09', 'period will be contacted for their survival status (excluding participants that have previously', 'recorded a death event in the collection tool).', '7.1.5.5 Second Course Phase', 'Subjects who have stable disease (SD), PR, or CR after receiving 35 pembrolizumab', 'treatments may be eligible for retreatment with up to an additional 17 cycles (approximately', '1 year) of pembrolizumab treatment. This retreatment is termed the Second Course Phase of', 'this trial and will only be available upon consultation with the Sponsor if the trial remains', 'open and if the subject meets the following conditions:', 'Had SD, PR, or CR and stopped treatment after completion of 35 administrations', '(approximately 2 years) of pembrolizumab in the Initial Treatment Phase.', '(Consultation with the Sponsor will be needed in those cases where pembrolizumab', 'was stopped for reasons other than disease progression or intolerability before', '35 cycles.)', 'AND', 'Experienced a BICR-verified radiographic disease progression by modified', 'RECIST 1.1 after stopping initial treatment, and', 'No new anticancer treatment was administered after the last dose of trial', 'treatment, and', 'The subject meets all of the safety parameters listed in the inclusion criteria', 'and none of the safety parameters listed in the exclusion criteria, and', 'The trial is ongoing.', 'Treatment assignment will be unblinded only for those subjects who meet all criteria for the', 'Second Course Phase. Subjects in the saline placebo arm are not eligible for the Second', 'Course Phase.', 'Procedures and assessments for the Second Course Phase will be initiated once radiographic', 'disease progression by modified RECIST 1.1 has been determined by the investigator and', 'verified by BICR, and the subject has met the criteria listed above. All procedures and', 'assessments completed at the time of withdrawal from the Initial Treatment Phase may be', 'used, as appropriate, for the start of the Second Course Phase of the study. Procedures and', 'assessments must be completed within 28 days after radiographic progression by modified', 'RECIST 1.1.', 'An objective response or disease progression that occurs during the Second Course Phase for', 'a subject will not be counted as an event for the primary analysis of any endpoint in this trial.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '92', 'Protocol/Amendment No.: 604-09', 'Visit requirements are outlined in the Trial Flow Chart (Section 6.2). Survival assessments', 'and their respective entries into the database may be required more frequently around the', 'time of the projected analyses (eg, DMC reviews, interim analyses).', 'Specific procedure-related details are provided above in Section 7.1.', '7.1.5.6 Continued Treatment Following Verified Progressive Disease', 'Subjects who are deemed by the investigator to be benefiting clinically despite documented', 'PD assessed by BICR using RECIST 1.1 (modified to follow a maximum of 10 target lesions', 'and a maximum of 5 target lesions per organ), may remain on study and continue receiving', 'the originally assigned trial treatment for a total of 35 cycles. Continued post-PD treatment is', 'optional and will be determined at the discretion of the investigator (in consultation with the', 'Sponsor).', 'Subjects who meet the following criteria will be eligible for continued post-PD treatment:', 'Documentation of PD will be defined as BICR assessment.', 'AEs (except alopecia and peripheral neuropathy) due to therapy must have improved', 'to NCI CTCAE 4.0 Grade <1.', 'If a subject is unstable as a result of a new or progressing brain metastasis(es), the', 'subject will not be eligible for continued treatment.', 'ECOG Performance Status of 0 or 1.', 'Subject must not have received any non-study systemic anti-cancer therapies.', 'Subject has adequate organ function as indicated by the laboratory assessments listed', 'in Section 5.1.2.', 'Visit requirements are outlined in the Trial Flow Chart (Section 6.1). Survival assessments', 'and their respective entries into the database may be required more frequently around the', 'time of the projected analyses (eg, DMC reviews, interim analyses). Specific procedure-', 'related details are provided above in Section 7.1.', '7.1.5.7 Discontinued Subjects Continuing to be Monitored in the Trial', 'Subjects who discontinue from the treatment phase prior to disease progression will continue', 'to be followed in PFS follow-up until they experience disease progression or start a new', 'antineoplastic therapy. Subjects with an AE of Grade >1 will be further followed until the', 'resolution of the AE to Grade 1 or until beginning of a new antineoplastic therapy,', 'whichever occurs first.', 'Date of disease recurrence or metastatic progression, start and stop dates of subsequent', 'anti-cancer treatments, and reasons for treatments should be recorded in the appropriate', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}